Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07151937 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of LAD191 in Adults With Hidradenitis Suppurativa

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Primary completion date: May 2027 to May 25, 2027 · Completion date: Nov 2027 to Nov 25, 2027 · 1 morev3 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: May 2027 to May 25, 2027
    • Completion date: Nov 2027 to Nov 25, 2027
    • Start date changed from estimate of Sep 2025 to Nov 5, 2025
  2. Eligibility criteria shortened, about 526 words Secondary endpoints expanded, about 71 words · Study description expanded, about 14 words · Study arms: 8 to 5v2 Show 3 more changesShow less
    • Secondary endpoints expanded, about 71 words
    • Study description expanded, about 14 words
    • Study arms: 8 to 5

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to assess the efficacy of multiple dosing regimens of LAD191 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS) and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.
Trial Details
NCT Number NCT07151937
Lead Sponsor Almirall, S.A.
Conditions Hidradenitis Suppurativa
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov